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Editorial

A new opportunity for MEMRI
Ryan Cloyd, Moriel Vandsburger, Jose F. Abisambra

Manganese enhanced magnetic resonance imaging
(MEMRI) has long been recognized as a potential tool
for radiologic studies. Lin and Koretsky significantly
expanded the utility of MEMRI when they showed that
it could provide non-invasive, in vivo measurement of
neuronal activity [1]. We recently showed that MEMRI
with ΔR1 mapping detects significant differences in
neuronal function between groups of wild type and tau
transgenic mice [2]. This study reinforces the potential
of MEMRI to be used in the early detection of neuronal
dysfunction associated with neurodegeneration by
showing differences in function before the development
of significant cognitive changes. A major challenge in
developing effective treatments for neurodegenerative
conditions is identifying patients while still within a
window of time where pharmacologic intervention can
be effective. Many drugs have shown diseasemodifying potential in animal models, but all have
failed in clinical trials. Therefore, MEMRI has the
potential to contribute to solving this problem, and
implementation of the technique in human populations
may allow more effective recruiting of participants for
drug trials.
A major hurdle translating MEMRI to humans is the
concern for toxicity upon overexposure to manganese
that may be associated with isolated or repeated
administration. Much of this concern stems from the
MSDS for manganese chloride, the most commonly
used manganese agent. However, MEMRI studies have
often exceeded the listed toxic doses without ill effects
[3]. Despite this and many additional examples
demonstrating the safety of manganese administration at
doses required for imaging, concern remains regarding
MEMRI in patients. In response, development of
mangafodipir (Teslascan, MnDPDP), a FDA approved
contrast agent, became a viable option to assuage these
concerns. Many clinical trials were performed using
MnDPDP in human populations in the early 1990s,
finding headache and nausea as the most severe side
effects reported by patients [4]. Most individuals
exposed to MnDPDP experience only facial flushing
that subsides within minutes of administration.
While numerous pre-clinical studies demonstrated
toxicity of MnCl2 at high doses, MnDPDP exhibits no
major toxicity in a variety of animal models at doses
much higher than those required for adequate image
enhancement [5]. Moreover, multiple clinical trials
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demonstrated tolerability to MnDPDP in human
subjects. These data suggest that with further safety
evaluation, MnDPDP may enable comprehensive
MEMRI examination in humans.
Although it remains a FDA-approved drug, MnDPDP is
not widely used for imaging studies. Currently, the
therapeutic role of MnDPDP is being investigated
including as a chemotherapy adjunct to prevent druginduced neuropathy and as a cardio-protectant following
acute myocardial infarction. The fodipir ligand
component of MnDPDP is a structural derivative of
vitamin B6 (which is commonly used to treat certain
types of neuropathy), but the anti-neuropathic effects of
MnDPDP more likely stem from its ability to scavenge
superoxide anions generated by many chemotherapeutics than from this structural similarity [6]. The
superoxide dismutase (SOD) activity of MnDPDP is
likely also the basis of its ability to prevent reperfusion
observed in a small study of human patients with acute
ST-elevation myocardial infarction [7]. Studies are
ongoing, but MnDPDP can be expected to attain a more
significant therapeutic role as its properties and activity
within the body are better understood. Therapeutic
doses generally exceed those required for imaging, so
advances in therapeutic studies, particularly those
demonstrating tolerability, will help pave the way for
future imaging applications.
Importantly, advances in the preclinical application of
MEMRI occurred concomitantly with technological
advances in imaging including high field 7T human
brain imaging, combined positron emission tomography
(PET) and MRI imaging, and targeted PET tracers for
the study of neurodegenerative diseases. While early
studies of MnDPDP that utilized clinical imaging
systems were restricted to field strengths of 1.5T and
3T, the increasing adoption of 7T human brain imaging
offers several important advantages. Beyond the ability
to resolve smaller substructures in the brain, the longer
T1 relaxation times of brain tissues at 7T extends the
dynamic range for quantitation of changes in T1 due to
manganese accumulation. Subsequently, further
reductions in MnDPDP dose could be pursued without
attenuation of sensitivity. Alternatively, existing doses
could be maintained and more subtle changes in
accumulation could be quantified. Finally, targeted PET
agent studies can be performed in parallel to MEMRI,
allowing for multiplexed molecular imaging of
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neurodegenerative disease biomarkers and neuronal
function. Together, these could provide a powerful
toolbox for comprehensive and earlier detection, as well
as longitudinal monitoring of response to pharmaceutical interventions that seek to attenuate disease
progression.
Therefore, MnDPDP has further use as an agent for
MEMRI. Despite safety concerns, numerous studies
[4][7]) show that MnDPDP is well tolerated in human
populations at the doses required for imaging or
therapeutic benefit. We are currently exploring a role
for MnDPDP in the imaging paradigm described in [2],
with promising early results. Once the efficacy of
MnDPDP to detect changes in neuronal function has
been established, the door will open for translational
studies involving human patients. MnDPDP was
quickly supplanted in its original role for imaging, but
recent years have given it a new purpose. The near
future may see a major return of mangafodipir to the
market and opportunities for MEMRI in translational
research.
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